Topic

Strimvelis (autologous CD34+ ADA-SCID gene therapy)

A collection of 39 issues

How to Get Strimvelis Gene Therapy Covered by Aetna CVS Health in Michigan: Complete Coding, Appeals & Authorization Guide

Answer Box: Getting Strimvelis Covered by Aetna CVS Health in Michigan Strimvelis (autologous CD34+ gene therapy for ADA-SCID) requires prior authorization from Aetna CVS Health in Michigan. Use ICD-10 code D81.31 and HCPCS J3590 for billing. Submit genetic confirmation, enzyme testing showing <1% ADA activity, and proof of

Work With Your Doctor to Get Strimvelis Gene Therapy Approved by UnitedHealthcare in Michigan: Provider Partnership Guide

Answer Box: Your Path to Approval Getting Strimvelis (autologous CD34+ ADA-SCID gene therapy) approved by UnitedHealthcare in Michigan requires strong provider partnership. Your doctor must submit prior authorization with confirmed ADA enzyme deficiency (<1% normal), genetic testing, HSCT ineligibility documentation, and medical necessity letter citing life-threatening urgency. If denied,

Getting Strimvelis Gene Therapy Covered by Humana in Virginia: Complete Timeline, Forms, and Appeals Guide

Answer Box: Fast Track to Strimvelis Coverage Getting Strimvelis covered by Humana in Virginia requires prior authorization with documented ADA enzyme deficiency (<1% normal), genetic confirmation of bi-allelic ADA mutations, and proof no suitable bone marrow donor exists. Submit via Humana's Clinical Pharmacy Review (800-555-2546) with medical

Getting Strimvelis Gene Therapy Covered by Blue Cross Blue Shield in California: Complete Coding, Appeals, and Authorization Guide

Quick Answer: Getting Strimvelis Covered by Blue Cross Blue Shield in California Blue Cross Blue Shield plans in California require prior authorization for Strimvelis (autologous CD34+ gene therapy for ADA-SCID), administered only at SR-TIGET in Milan, Italy. Use ICD-10 code D81.31 (severe combined immunodeficiency due to adenosine deaminase deficiency)

How to Get Strimvelis Gene Therapy Covered by Blue Cross Blue Shield in Ohio: Complete Appeal Guide with Forms and Timelines

Answer Box: Getting Strimvelis Covered in Ohio Strimvelis (ADA-SCID gene therapy) requires prior authorization from Blue Cross Blue Shield in Ohio, with appeals following a structured timeline: internal review (30 days), second-level appeal if needed, then external review through Ohio's Independent Review Organization (180-day deadline from final denial)

Denied for Strimvelis Gene Therapy by Cigna in Texas? Complete Appeal Guide with Forms & Timelines

Answer Box: Getting Strimvelis Covered by Cigna in Texas Strimvelis (autologous CD34+ ADA-SCID gene therapy) requires prior authorization from Cigna and is often initially denied as "experimental." To get coverage in Texas: (1) Gather genetic testing confirming ADA-SCID, enzyme deficiency results, and HLA typing showing no matched related

If Strimvelis (ADA-SCID Gene Therapy) Isn't Approved by Blue Cross Blue Shield in Florida: Alternative Treatments & Exception Paths

Answer Box: Your Options When Strimvelis Gene Therapy Is Denied If Blue Cross Blue Shield (BCBS) in Florida denies Strimvelis gene therapy for ADA-SCID, you have three main paths: PEG-ADA enzyme replacement therapy as a bridge treatment, allogeneic stem cell transplant if a donor is available, or formulary exception appeal

How to Get Strimvelis Gene Therapy Covered by Humana in Michigan: Coding, Appeals, and Authorization Guide

Answer Box: Getting Strimvelis Covered by Humana in Michigan Strimvelis requires prior authorization from Humana using ICD-10 code D81.1 (ADA-deficient SCID) and unclassified HCPCS codes C9399 or J3590 since it lacks a specific J-code. Submit PA requests to Humana National Transplant Network at 866-421-5663 or fax 502-508-9300. If denied,

How to Get Strimvelis Gene Therapy Covered by Aetna CVS Health in Illinois: Complete Prior Authorization and Appeals Guide

Answer Box: Get Strimvelis Covered by Aetna CVS Health in Illinois Strimvelis gene therapy for ADA-SCID requires prior authorization from Aetna CVS Health with genetic confirmation of biallelic ADA mutations, enzyme activity <1% normal, and documented failures of PEG-ADA therapy. Submit through the Aetna provider portal with a medical

How to Get Strimvelis Gene Therapy Covered by Blue Cross Blue Shield in Illinois: Complete Guide to International Treatment Authorization and Appeals

Answer Box: Getting Strimvelis Covered in Illinois Strimvelis gene therapy for ADA-SCID requires special authorization from Blue Cross Blue Shield of Illinois (BCBSIL) as an experimental/international treatment. Start by calling BCBSIL member services at 1-800-892-2803 to verify international coverage benefits and request experimental treatment exception forms. Submit comprehensive medical